The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials
Therapeutic Innovation & Regulatory Science · 2025
DOI: 10.1007/s43441-025-00774-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Hanke Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Pharmaceutical Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Drug Development, Drug Industry, Clinical Trials as Topic, Drug Costs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The Inflation Reduction Act’s (IRA) Drug Price Negotiation Program (DPNP) may reduce incentives for industry investments in post-approval clinical development. We aimed to explore the IRA’s impact on the initiation of industry-sponsored, post-approval clinical trials.
Methods
Using Citeline’s Trialtrove database (7/2014–8/2024), we conducted an interrupted time series analysis (ITSA) to estimate the IRA’s impact on the initiation of industry-sponsored Phase I-III trials in previously approved drugs, excluding all vaccines and COVID-19 treatments. We conducted an additional ITSA to examine post-IRA changes in government-funded trials, hypothesized to be unaffected by the IRA, and sensitivity analyses to explore potential exogenous confounding factors. Finally, we explored differences in the IRA’s impact on post-approval industry-sponsored clinical trial initiation in small versus large molecule drugs.
Results
Following the IRA’s passage, the average monthly number of industry-sponsored trials on post-approval drugs decreased by 38.4%. The ITSA indicated that the IRA’s passage was associated with an immediate drop of 11.1 industry-sponsored trials (p-value < 0.05) and an additional decrease by 0.9 trials per month (p-value < 0.01). The IRA’s passage was not statistically associated with changes in government-funded trial initiation. Sensitivity analyses supported ITSA findings. Initiation of post-approval industry-sponsored trials decreased by 47.3% and 32.9% for small and large molecule drugs, respectively.
Conclusions
The IRA’s passage was associated with reductions in industry-sponsored, but not government-funded, post-approval trials, with larger reductions for small molecule drugs. These findings provide early evidence supporting concerns around IRA-related reductions in incentives for post-approval clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Pharmaceutical Council, Washington, DC, USA.
- National Pharmaceutical Council, Washington, DC, USA. jcampbell@npcnow.org.
Zitieren
APA
Zheng, H., Patterson, J. A., & Campbell, J. D. (2025). The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00774-2
Vancouver
Zheng H, Patterson JA, Campbell JD. The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00774-2
BibTeX
@article{Zheng2025,
author = {Zheng, Hanke and Patterson, Julie A and Campbell, Jonathan D},
title = {The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
doi = {10.1007/s43441-025-00774-2}
}
EUVIMED